| Expression pattern: |
UP |
| Associated gene: |
DNMT3A, AGO2 |
| Associated microRNA: |
hsa-miR-143-3p |
| Biological function: |
Promotes pancreatic ductal adenocarcinoma cell aerobic glycolysis, epithelial-mesenchymal transition, and cell viability; knockdown inhibits glycolytic capacity and EMT-related protein changes. |
| Molecular mechanism: |
hsa_circ_0084003 acts as a ceRNA sponge for hsa-miR-143-3p, thereby regulating DNMT3A expression and promoting aerobic glycolysis and EMT in PDAC cells. |
| Biological pathway or process: |
glycolysis (promotes); EMT (promotes); proliferation (promotes); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Nuclear-Cytoplasmic Fractionation; Transfection; CCK8; Western Blot; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Bioinformatics Analysis |
| Clinical significance: |
hsa_circ_0084003 could be studied as a possible therapeutic target and potential biomarker for PDAC targeted therapy. |
| Description: |
This study identifies hsa_circ_0084003 as a pro-oncogenic circRNA in PDAC cell models. It promotes aerobic glycolysis and EMT by sponging hsa-miR-143-3p and regulating DNMT3A, suggesting potential value as a targeted therapeutic biomarker. |
| Confidence score: |
0.7716 |